# Clinical, Histopathological, and Molecular Prognostic Factors Associated With Survival and Disease Progression in Adult Patients With Primary and Secondary Thyroid Lymphomas: Scoping Review Protocol

## TL;DR

This study aims to identify clinical, histopathological, and molecular factors that affect survival and disease progression in patients with thyroid lymphomas.

## Contribution

The study introduces a scoping review protocol to systematically analyze prognostic factors in primary and secondary thyroid lymphomas.

## Key findings

- A literature search retrieved 1404 results from databases like Scopus, MEDLINE, and EMBASE.
- The review will focus on observational studies of adult patients with thyroid lymphoma.
- The findings may help identify patients at risk for aggressive disease and guide treatment decisions.

## Abstract

To identify the key prognostic factors in patients with primary and secondary thyroid lymphoma, focusing on clinical, histopathological, biological, and genetic components, as these factors remain unclear.The key prognostic factors in patients with primary and secondary thyroid lymphoma remain unclear, particularly regarding clinical, histopathological, biological, and genetic components.

This study aimed to analyze and synthesize the available evidence to identify factors that may influence the prognosis of patients with primary and secondary thyroid lymphoma.

This review will include indexed databases such as Scopus, Ovid-MEDLINE, and EMBASE as the primary search sources. The search strategy was applied during the period from June 1, 2024, to September 1, 2024, encompassing all available literature. Eligibility criteria include observational studies of human patients aged 18 years or older, with a diagnosis of primary and/or secondary thyroid lymphoma. We will include reports of adult cases diagnosed with primary thyroid lymphoma or secondary thyroid lymphoma and exclude studies involving patients with primary or secondary tumors of an origin other than thyroid lymphoma. Additionally, studies reporting patients who, alongside primary or secondary thyroid lymphoma, have concomitant diseases associated with high morbidity or mortality, will be excluded. A total of two independent reviewers will participate in the screening, selection, and data extraction process, all of which will be carried out blindly. Conflicts between reviewers will be resolved through discussion or by involving an additional reviewer. Results will be reported using descriptive statistics, and the information will be stored in RedCap (Electronic Research Data Capture).

The literature search was conducted in August 2024, using the following databases: Scopus, MEDLINE, and EMBASE, to identify observational studies. A total of 1404 results were retrieved. The scoping review is expected to be completed by August 2025.

This scoping review will describe the current understanding of the prognostic factors that influence the course of the disease in patients diagnosed with primary and secondary thyroid lymphoma. The review will highlight characteristics that may identify patients at risk of more aggressive disease behavior and could potentially guide therapeutic decisions. Future studies should assess the incidence of these prognostic factors across different age groups and explore their clinical correlations.